GlassScriptPhysician profile
Timothy W Doyle
NPI 1548376510
$2,401.23
in general payments reported to CMS, 2019-2025
23 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $27.30 · 2021: $40.46 · 2022: $512 · 2023: $1,135 · 2024: $326 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,821.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $315.91 | 2020-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $296.37 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $273.96 | 2022-2024 | Farxiga, Breztri |
| Pfizer INC. | $225.63 | 2022-2024 | |
| Abbvie INC. | $225.28 | 2021-2025 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $216.78 | 2022-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $191.34 | 2022-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $114.15 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $68.11 | 2023-2024 | Eliquis |
| Exact Sciences Corporation | $64.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $55.96 | 2022-2023 | Quviviq |
| Amgen INC. | $52.82 | 2022-2025 | Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.95 | 2022-2023 | Jardiance, Tradjenta |
| Abbott Laboratories | $46.36 | 2023 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $45.00 | 2024 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $33.17 | 2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $28.97 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $20.38 | 2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $17.19 | 2023 | Rexulti |
| Electromed, INC. | $15.67 | 2023 | Smartvest |
| Alexion Pharmaceuticals, INC. | $15.21 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.14 | 2022 | |
| Harmony Biosciences LLC | $14.72 | 2023 | Wakix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.